Because ACC1/2 dual inhibitors and ACC1-specific inhibitors are associated with MASLD improvement along with the adverse effect of hypertriglyceridemia, it is tempting to speculate that ACC2-specific inhibitors could lead to increased FAO rates and, thereby, improved MASLD in the absence of dyslipidemia. The gene discussed is ACACA; the disease is metabolic syndrome.